Myrtle Potter - Myovant Sciences Chairman of the Board

MYOV -  USA Stock  

USD 20.88  0.06  0.29%

  Chairman
Ms. Myrtle Stephens Potter is Chairman of the Board of the Company. She has served as Vant Operating Chair of Roivant Sciences, Inc., a whollyowned subsidiary of Myovants controlling shareholder, Roivant Sciences Ltd., since July 2018. In addition to serving on the Board, Ms. Potter is expected to serve on the board of directors of certain other subsidiaries of Roivant Sciences Ltd. Ms. Potter founded Myrtle Potter Company, LLC, a private healthcare and life sciences consulting firm, in September 2005, and served as the Chief Executive Officer until July 2018. From August 2009 until December 2014, Ms. Potter served as Founder and Chief Executive Officer of Myrtle Potter Media, Inc., a consumer healthcare company. From 2000 to 2004, Ms. Potter served as Chief Operating Officer at Genentech, Inc., a biopharmaceutical company, and from 2004 to 2005, she served as the President, Commercial Operations and Executive Vice President of Genentech. Prior to that, Ms. Potter held various positions, including President, CardiovascularMetabolics at BristolMyers Squibb and a vice president at Merck Co. Ms. Potter currently serves on the boards of directors of Rite Aid Corporationrationration, a leading drugstore chain, Liberty Mutual Holding Company Inc., a diversified global insurance company, Axsome Therapeutics, Inc., a biopharmaceutical company, INSMED Incorporated, a biopharmaceutical company, and a number of privately held companies. Ms. Potter previously served on the boards of directors of Everyday Health, Inc., a leading provider of digital health and wellness solutions, from October 2010 until its acquisition in December 2016, and Amazon.com, Inc., a leading ecommerce company, from 2004 to 2009. She also served on the boards of directors of Medco Health Solutions Inc. and Express Scripts Holding Co., subsequent to its acquisition of Medco Health Solutions, as well as other privately held companies
Age: 61  Chairman Since 2018      
44 20 7400 3351  http://myovant.com
Potter earned a B.A. from the University of Chicago.

Myrtle Potter Latest Insider Activity

Tracking and analyzing the buying and selling activities of Myrtle Potter against Myovant Sciences stock is an integral part of due diligence when investing in Myovant Sciences. Myrtle Potter insider activity provides valuable insight into whether Myovant Sciences is net buyers or sellers over its current business cycle. Note, Myovant Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Myovant Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Myovant Sciences Management Efficiency

Myovant Sciences has return on total asset (ROA) of (35.36) % which means that it has lost $35.36 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 20.67 %, meaning that it created $20.67 on every $100 dollars invested by stockholders. Myovant Sciences management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Equity is likely to climb to 1.09 in 2021, whereas Return on Average Assets are likely to drop (0.63)  in 2021. Myovant Sciences Total Assets are fairly stable at the moment as compared to the past year. Myovant Sciences reported Total Assets of 725.03 Million in 2020. Current Assets is likely to climb to about 760.3 M in 2021, whereas Return on Average Assets are likely to drop (0.63)  in 2021.
The company currently holds 369.7 M in liabilities with Debt to Equity (D/E) ratio of 138.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Myovant Sciences has a current ratio of 2.46, suggesting that it is liquid enough and is able to pay its financial obligations when due.
The market value of Myovant Sciences is measured differently than its book value, which is the value of Myovant that is recorded on the company's balance sheet. Investors also form their own opinion of Myovant Sciences' value that differs from its market value or its book value, called intrinsic value, which is Myovant Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myovant Sciences' market value can be influenced by many factors that don't directly affect Myovant Sciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myovant Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Myovant Sciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myovant Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Found 1 records

CHAIRMAN Since

Arnold OronskyDynavax Technologies
2006
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womens health and endocrine diseases. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. Myovant Sciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 407 people. Myovant Sciences (MYOV) is traded on New York Stock Exchange in USA. It is located in 11-12 St. James’s Square and employs 407 people. Myovant Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Myovant Sciences Leadership Team

Elected by the shareholders, the Myovant Sciences' board of directors comprises two types of representatives: Myovant Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Myovant. The board's role is to monitor Myovant Sciences' management team and ensure that shareholders' interests are well served. Myovant Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Myovant Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Keith Manchester, Director
Frank Karbe, Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc.
Juan Ferreira, Chief Commercial Officer - Myovant Sciences, Inc
Marianne Romeo, Head, Global Transactions & Risk Management
Mark Altmeyer, Independent Director
Frank Torti, Director
Vivek Ramaswamy, Director
Jeffrey Nornhold, Senior Vice President Pharmaceutical Operations & Development
Kim Sablich, Chief Commercial Officer
Wayne DeVeydt, Independent Director
Matthew Lang, General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc.
Kathleen Sebelius, Lead Independent Director
Adele Gulfo, Director, Interim Chief Commercial Officer
Mark Guinan, Independent Director
Myrtle Potter, Chairman of the Board
David Marek, Principal Executive Officer, Director
Terrie Curran, Independent Director
Hiroshi Nomura, Director
Lynn Seely, Principal Executive Officer, Director

Myovant Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Myovant Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Myovant Sciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Global Markets Map Now

   

Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Myovant Sciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Myovant Sciences information on this page should be used as a complementary analysis to other Myovant Sciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Myovant Stock analysis

When running Myovant Sciences price analysis, check to measure Myovant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Myovant Sciences is operating at the current time. Most of Myovant Sciences' value examination focuses on studying past and present price action to predict the probability of Myovant Sciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Myovant Sciences' price. Additionally, you may evaluate how the addition of Myovant Sciences to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
The market value of Myovant Sciences is measured differently than its book value, which is the value of Myovant that is recorded on the company's balance sheet. Investors also form their own opinion of Myovant Sciences' value that differs from its market value or its book value, called intrinsic value, which is Myovant Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myovant Sciences' market value can be influenced by many factors that don't directly affect Myovant Sciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myovant Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Myovant Sciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myovant Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.